Dogwood Therapeutics Advances Non-Opioid Pain Pipeline with Phase 2b Data Expected This Fall
Dogwood Therapeutics reported first quarter 2026 financial results, highlighting progress in its non-opioid pain treatments Halneuron and SP16, with key clinical milestones expected in 2026.
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced its first quarter 2026 financial results on May 14, 2026, revealing operational momentum with significant pipeline advancements for its non-opioid pain therapies. The company reported a net loss attributable to common stockholders of $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the same period last year.
The improved bottom line reflects reduced expenses related to debt conversion and lower preferred stock dividends, while research and development costs rose modestly to $2.7 million from $2.4 million, driven by increased spending on Halneuron and personnel costs. General and administrative expenses increased to $2.4 million from $2.0 million, primarily due to higher salaries. As of March 31, 2026, the company held $13.2 million in cash, which it expects to fund operations into the fourth quarter of 2026.
Dogwood's lead candidate, Halneuron, a non-opioid NaV 1.7 inhibitor for chemotherapy-induced neuropathic pain (CINP), has enrolled 164 patients in its Phase 2b trial. Top-line results are anticipated in fall 2026. Halneuron has received Fast Track designation from the U.S. Food and Drug Administration. The company's second candidate, SP16, a low-density lipoprotein receptor related protein-1 (LRP1) agonist, received FDA clearance to begin a Phase 1b trial for chemotherapy-induced pain and peripheral neuropathy (CIPPN) in mid-2026. This trial is fully funded by the National Cancer Institute and will be conducted at the University of Virginia. Preclinically, SP16 has shown potential anti-inflammatory and tissue-repairing actions.
CEO Greg Duncan emphasized the importance of these milestones, noting that the company executed a global development license for its legacy combination antiviral assets, further streamlining its focus on pain therapeutics. In January 2026, Dogwood completed a financing of up to $26.9 million, with $12.5 million received in gross proceeds, to support Halneuron's development.
The implications of these developments are significant for patients seeking non-opioid alternatives for chronic pain. With the opioid crisis persisting, advancing therapies like Halneuron and SP16 could address a critical unmet medical need. The company's pipeline targets neuropathic pain, a condition often poorly managed by existing treatments. If successful, these candidates could offer new options for millions of cancer survivors suffering from chemotherapy-induced pain.
Dogwood Therapeutics, based in Alpharetta, GA, is a development-stage biopharmaceutical company focused on first-in-class non-opioid medicines. Its largest shareholder is a member of CK Life Sciences Int'l. (Holdings) Inc., listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, visit www.dwtx.com.